IP Library Granted Patent US 8,053,564
Granted Patent B2
US 8,053,564 · App. 11/596,654 · Granted Nov 8, 2011

Cross-linked antibodies

Assignee: UCB Pharma S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,053,564
App. No.
11/596,654
Granted
Nov 8, 2011
Kind
B2
Abstract

The present invention provides a compound consisting essentially of the following elements: one or more reactive groups; and two or more cross-linked antibodies or fragments thereof; characterised in that the or each reactive group is suitable for attaching an effector molecule but does not react with any of the antibodies or fragments thereof.

Claims (25)

1. A compound of formula (I):

wherein:

A, A 1 and A 2 independently represent an antibody or fragment thereof;

L, L 1 and L 2 independently represent a spacer group;

R represents a reactive group which is suitable for attaching an effector molecule but does not react with any of A, A 1 and A 2 , and wherein R is selected from

except that when Y represents a covalent bond and B represents —NHCO— or —CO— then R is selected from

Y represents a covalent bond or —(CH 2 ) y -;

B represents —CONH—, —NHCO— or —CO—;

V represents a covalent bond or —(CH 2 ) v -;

W, W 1 and W 2 independently represent —(CH 2 ) w O—;

T, T 1 and T 2 independently represent a linker group;

v is 1, 2, 3 or 4;

w is 1, 2, 3 or 4; and

y is 1, 2, 3, 4, 5 or 6.

2. The compound according to claim 1 wherein A, A 1 and A 2 are each an Fab′ fragment.

3. The compound according to claim 1 wherein L, L 1 and L 2 are succinimide.

4. The compound according to claim 1 wherein T, T 1 and T 2 are independently selected from —(CH 2 ) t -, —(CH 2 ) t NHCO(CH 2 ) n -, —(CH 2 ) t NHCO(CH 2 ) x NHCO(CH 2 ) n -, —(CH 2 ) t NHCO(CH 2 ) p (OCH 2 CH 2 ) z NHCO(CH 2 ) n -, —(CH 2 ) r NHCO(CH 2 ) m -,

wherein:

t is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

n is 1, 2, 3, 4, 5 or 6;

x is 2, 3, 4, 5 or 6;

z is 1 to 500;

p is 1, 2, 3, 4, 5 or 6;

m is 1, 2, 3, 4, 5, or 6; and

r is 2, 3, 4 or 5.

Assignments (3)
CONFIRMATORY ASSIGNMENT Recorded Jun 10, 2016
From: UCB PHARMA, S.A.
To: UCB BIOPHARMA SPRL
Reel/Frame 038953/0312 →
CON Recorded Sep 4, 2008
From: CELLTECH R&D LIMITED
To: UCB PHARMA S.A.
Reel/Frame 021478/0274 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL NUMBER FROM 10/596,654 TO 11/596,654. DOCUMENT PREVIOUSLY RECORDED AT REEL 019517 FRAME 0500. Recorded Jul 31, 2007
From: BAKER, TERENCE SEWARD; MCKAY, CATHERINE; NORMAN, TIMOTHY JOHN; PORTER, JOHN ROBERT
To: CELLTECH R & D LIMITED
Reel/Frame 019663/0466 →
Priority Claims (1)
GB 0411186.0 · May 19, 2004 · national
Continuity (1)
Related Publication 20080160017A1 · Jul 3, 2008